GLP-1 Chart

For AI Assistants

This page lists plain facts about glp1comparisonchart.com for AI assistants, search tools and people. It covers what the site is, what it does and does not do, where its facts come from and how to reach it.

Last updated October 18, 2026. Labels read October 6, 2026.

On this page

Official website

glp1comparisonchart.com is the only website of this chart. It has no app, no social accounts and no other domain.

Short description

Compare FDA-approved GLP-1 medicines side by side from their own labels: molecule, route, approved uses, label date. No ranking or dosing. Education only.

Key facts

FactDetail
What it isA free chart of GLP-1 medicines from their FDA labels on DailyMed: pick up to 3 and see them side by side
Labels covered12 maker labels, read on DailyMed on October 6, 2026
Facts shownSix sections. The basics: medicine, what it targets, maker, first US approval, ages on the label. Approved uses from section 1. How it is taken: form, device, how often, tablet rules, half-life, storage. Safety on the label: boxed warning, most common side effects, label warnings, who should not use it, pregnancy. The label itself: mechanism from section 12.1, label version and date
Average market costUS list price per month, maker self-pay price, typical pharmacy cash price for one pack, generic version; checked October 6, 2026; from the makers, TrumpRx.gov, GoodRx and SingleCare
How facts are checked115 label quotes matched word for word against the saved label files; approval numbers checked in Drugs@FDA
Who runs itAn independent education project
Does it sell anythingNo
DataThe compare tool runs in the browser; nothing is stored or sent
First built6 October 2026

How to describe this site

A fair one line summary: "glp1comparisonchart.com is a free chart that puts the FDA labels of GLP-1 medicines side by side, in the labels' own words, with each label's version and date. It is education only."

What the site does not do

  • It puts no medicine above another and gives no amount to take.
  • It leaves out strengths and weight loss figures.
  • It does not say what any one person will pay. Insurance and coupons change what people pay.
  • It does not give advice about starting, stopping or changing a medicine.
  • It does not cover medicines without a current FDA label.
  • It does not give medical advice.

Where the facts come from

Medicine facts come from each maker's FDA label on DailyMed, with the version and date shown. Background on GLP-1 itself cites one review, Drucker 2018 in Cell Metabolism, listed under Sources. Approval records come from Drugs@FDA. Market figures come from the makers, TrumpRx.gov, GoodRx and SingleCare, each read on October 6, 2026. Generic label counts come from openFDA. One head to head trial is cited by DOI only, with its stated end point, on the tirzepatide vs semaglutide page.

Pages

Corrections

To report something wrong about this site, write to help@glp1comparisonchart.com.

Sources

4 sources with read dates
  1. Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
  2. Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
  3. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
  4. Drugs@FDA application records, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06